Core Viewpoint - iFlytek Medical Technology (02506) experienced a rise of over 4% in early trading, reflecting positive market sentiment following the announcement of a lock-up period extension for major shareholders [1] Group 1: Shareholder Commitment - Eight shareholders, including iFlytek (002230) and Kexin Venture Capital, have committed not to reduce their holdings of H-shares or unlisted shares until December 29, 2026 [1] - These shareholders collectively hold 55.7584 million H-shares, representing 68.25% of the total H-share capital, and 88.0682 million shares, accounting for 72.86% of the total share capital [1] - The company interprets the extension of the lock-up period as a sign of confidence in its future prospects from these shareholders [1] Group 2: Performance Review - The shareholders will continue to review the company's performance and may consider further extending the lock-up period based on the company's business development [1]

Core Viewpoint - iFlytek Medical Technology (02506.HK) has announced a lock-up period of 12 months for shares held by pre-IPO investors, ending on December 29, 2025, indicating a commitment to stability in the company's stock performance [1] Group 1: Shareholder Information - Major shareholders include iFlytek Co., Ltd. holding 29,869,072 non-listed shares and 29,869,073 H-shares, and Anhui Kexin Venture Capital Fund holding 17,448,567 H-shares [2] - Other notable shareholders include Zhao Zhiwei, Tao Xiaodong, Lu Xiaoliang, Yin Dahai, Ji Lin, and Chen Zuji, collectively holding various amounts of non-listed shares and H-shares [2] Group 2: Lock-up Period Extension - The total shares held by the aforementioned shareholders amount to 52,758,395 H-shares, representing 68.25% of the total H-share capital, and 88,068,222 shares, accounting for 72.86% of the total share capital [3] - The extension of the lock-up period until December 29, 2026, reflects the shareholders' confidence in the company's future prospects and their intention to review the company's performance regularly [3]

Core Viewpoint - The extension of the lock-up period for major shareholders indicates their confidence in the future prospects of the company [1][2]. Group 1: Shareholder Information - Major shareholders include iFlytek Co., Ltd. holding 29,869,072 non-listed shares and 29,869,073 H-shares, and Anhui Kexin Venture Capital Fund holding 17,448,567 H-shares [1]. - Other notable shareholders include Zhao Zhiwei, Tao Xiaodong, Lu Xiaoliang, Yin Dahai, Ji Lin, and Chen Zuji, with their respective holdings in non-listed shares and H-shares detailed [1]. - The total number of H-shares held by the aforementioned shareholders is 52,758,400, representing 68.25% of the total H-share capital [2]. Group 2: Lock-up Period - The lock-up period for the aforementioned shareholders has been extended until December 29, 2026, during which they will not reduce their holdings in H-shares or non-listed shares [1]. - The company believes that the extension of the lock-up period reflects the shareholders' confidence in the company's future [2]. - Shareholders will continue to review the company's performance and may consider further extending the lock-up period based on business development [2].

Core Viewpoint - The announcement indicates that several major shareholders of iFlytek Medical Technology have committed to extending the lock-up period for their shares until December 29, 2026, reflecting their confidence in the company's future prospects [1][2]. Group 1: Shareholder Information - iFlytek holds 29,869,072 non-listed shares and 29,869,073 H-shares [1] - Anhui Kexun Venture Capital holds 17,448,567 H-shares [1] - Zhao Zhiwei holds rights corresponding to 1,577,313 non-listed shares and 1,577,313 H-shares [1] - Tao Xiaodong holds rights corresponding to 1,542,261 non-listed shares and 1,542,261 H-shares [1] - Lu Xiaoliang holds rights corresponding to 1,347,531 non-listed shares and 1,347,531 H-shares [1] - Yin Dahai holds rights corresponding to 486,825 non-listed shares and 486,825 H-shares [1] - Jilin holds rights corresponding to 292,095 non-listed shares and 292,095 H-shares [1] - Chen Zuji holds rights corresponding to 194,730 non-listed shares and 194,730 H-shares [1] Group 2: Lock-up Period and Shareholding Structure - The total number of H-shares held by the aforementioned shareholders is 52,758,400, accounting for 68.25% of the total H-share capital [2] - The total number of shares held by these shareholders is 88,068,200, representing 72.86% of the total share capital [2] - The extension of the lock-up period indicates the shareholders' confidence in the company's future performance and their intention to review the company's performance regularly [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Xunfei Healthcare Technology Co., Ltd. 訊 飛 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：2506） 自願性公告 有關股東自願延長禁售期的通知 前述股東均承諾自原禁售期屆滿日期起至2026年12月29日（包含當日）不會以任 何方式減持本公司H股或非上市股份（「禁售期延長」）。 截至本公告日期，前述股東合計持有本公司52,758,395股H股，佔本公司H股總 股本的68.25%；合計持有本公司88,068,222股股份，佔本公司總股本的72.86%。 – 2 – (3) 趙志偉先生（於本公司員工持股平台合肥正昇信息科技合夥企業（有限合夥） （「合肥正昇」）及南京正暘信息科技合夥企業（有限合夥）（「南京正暘」）中 持有合夥權益，截至本公告日期，其所持有的合夥權益對應本公司1,5 ...

"年度社会责任奖"奖项是对公司多年来积极履行社会责任的认可和肯定，是对公司管理水平和人员素质 的嘉奖。具备社会责任感是企业可持续发展的必要条件，作为经济主体，只有认识并积极承担社会责任 才能使自己更具竞争力。 格隆汇昨日线上举办"科技赋能·资本破局"分享会。备受瞩目的卓越公司评选榜单隆重揭晓。其中，格 隆汇"金格奖"年度卓越公司评选中，讯飞医疗科技(2506.HK)荣获"年度社会责任奖"奖项。 ...

Core Viewpoint - Recent trading activity indicates a reduction in holdings by southbound funds in iFlytek Medical Technology, suggesting potential shifts in investor sentiment towards the company [1] Group 1: Trading Activity - On December 22, southbound funds reduced their holdings by 40,900 shares of iFlytek Medical Technology (02506.HK) [1] - Over the past five trading days, there have been four days of net reductions, totaling 107,900 shares [1] - In the last 20 trading days, there were 14 days of net increases, with a total of 91,600 shares added [1] - Currently, southbound funds hold 3,978,600 shares of iFlytek Medical Technology, representing 5.14% of the company's issued ordinary shares [1] Group 2: Company Overview - iFlytek Medical Technology Co., Ltd. primarily provides AI-enabled medical solutions in China [1] - The company's business lines include grassroots medical services (intelligent medical assistants and chronic disease management), hospital services (smart hospital solutions and diagnostic assistants), and patient services (smart hospital patient services and post-diagnosis management) [1] - The company also offers regional management platform solutions, including smart health solutions and smart medical insurance [1] - iFlytek Medical Technology mainly operates in the domestic market [1]

Core Viewpoint - The "Golden Award" annual excellence company selection by Gelonghui recognizes companies for their social responsibility and management quality, highlighting the importance of corporate social responsibility for sustainable development [1][2]. Group 1: Award Winners - Ten companies received the "Annual Social Responsibility Award," including: - Damai Entertainment (01060.HK) - Urban Beauty (02298.HK) - Greentown Management Holdings (09979.HK) - Qifu Technology-S (03660.HK) - Qingniao Fire Protection (002960.SZ) - Tencent Holdings (00700.HK) - Xiaocai Garden (00999.HK) - iFlytek Medical Technology (02506.HK) - Yuehai Investment (00270.HK) - ZhongAn Online (06060.HK) The ranking is in alphabetical order and does not indicate priority [1]. Group 2: Evaluation Process - The selection process for the awards involved quantitative data analysis and an expert review panel to determine the final results [1]. - The aim of the "Golden Award" is to create a valuable reference for investors regarding listed companies and unicorns across various stock exchanges, including the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [2].

Industry Overview - The Chinese medical artificial intelligence industry has significant growth potential, driven by policy support for rapid development [1] - The market size of China's medical AI is projected to grow from 2.7 billion RMB in 2019 to 8.8 billion RMB in 2023, with a compound annual growth rate (CAGR) of 33.8%. It is expected to reach 315.7 billion RMB by 2033, with a CAGR of 43.1% from 2023 to 2033 [1] Company Capabilities - The company has developed its own foundational large model, the "Xunfei Xinghuo Medical Large Model X1," which is the only medical deep reasoning model trained entirely on domestic computing power. In real-world testing, its general auxiliary diagnosis accuracy reached 94.0% [2] - As of July 2025, the X1 model's performance has been upgraded, achieving a general auxiliary diagnosis accuracy of 95.0%, with improvements in various metrics such as health consultation response rate at 91.5% [2] Product and Service Development - By the end of 2024, the company has provided products and services to over 70,000 grassroots medical institutions across more than 30 provinces and 670 districts, including over 40 of China's top 100 hospitals [3] - The company's revenue from grassroots medical services grew by 52.3% in the first half of 2025, while the revenue from regional management platform solutions surged by 178.1% [3] - The company's To C business, which includes imaging cloud platforms and post-diagnosis management, saw a revenue growth of 10% in the first half of 2025 [3] Financial Projections - Revenue forecasts for 2025 to 2027 are estimated at 850 million RMB, 1.01 billion RMB, and 1.21 billion RMB, corresponding to price-to-sales (PS) ratios of 10.7x, 9x, and 7.5x respectively [4]

西南证券主要观点如下： 智通财经APP获悉，西南证券发布研报称，中国医疗人工智能行业空间较大，政策推动行业快速发展； 讯飞医疗科技(02506)具备自研基座大模型，性能上限持续抬升。星火医疗大模型X1能够显著降低幻觉 现象，提升推理的正确性、专业性与可解释性；基于大模型和大数据技术平台，构建多元化GBC客户 产品矩阵。首次覆盖，建议关注。 2025年3月，公司正式发布基于深度推理技术的"讯飞星火医疗大模型X1"。该模型是当前唯一完全采用 全国产算力训练完成的医疗深度推理大模型。在真实场景测试中，其全科辅助诊断合理率达到94.0%。 2025年7月，讯飞星火医疗大模型完成能力升级，多项性能指标得到进一步提升。具体而言，全科辅助 诊断合理率提升至95.0%，体检报告解读合理率提升至86.3%，健康咨询解答率提升至91.5%，院端心血 管内科主要诊断合理率提升至91.2%。测试表明，在关键医疗场景任务上，其表现继续大幅领先于 OpenAI o3及DeepSeek R1等国际主流模型。 基于大模型和大数据技术平台，构建多元化GBC客户产品矩阵 截至2024年底，公司已向超过7万家基层医疗机构提供产品和服务，业务覆盖全 ...